Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $1.7 million.

  • Viking Therapeutics' Amortizatization of Intangibles fell 5705.78% to $1.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.3 million, marking a year-over-year decrease of 4623.27%. This contributed to the annual value of $9.3 million for FY2025, which is 4623.27% down from last year.
  • As of Q4 2025, Viking Therapeutics' Amortizatization of Intangibles stood at $1.7 million, which was down 5705.78% from $2.0 million recorded in Q3 2025.
  • Over the past 5 years, Viking Therapeutics' Amortizatization of Intangibles peaked at $5.4 million during Q2 2024, and registered a low of -$1.1 million during Q1 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $1.8 million (2023), whereas its average is $1.5 million.
  • In the last 5 years, Viking Therapeutics' Amortizatization of Intangibles plummeted by 11184.31% in 2021 and then surged by 499811.32% in 2023.
  • Quarter analysis of 5 years shows Viking Therapeutics' Amortizatization of Intangibles stood at -$755000.0 in 2021, then soared by 107.02% to $53000.0 in 2022, then soared by 4998.11% to $2.7 million in 2023, then surged by 49.19% to $4.0 million in 2024, then crashed by 57.06% to $1.7 million in 2025.
  • Its Amortizatization of Intangibles was $1.7 million in Q4 2025, compared to $2.0 million in Q3 2025 and $2.4 million in Q2 2025.